Detection of 1-Benzylpiperazine, 1-(3-Trifluoromethylphenyl)-piperazine, and 1-(3-Chlorophenyl)-piperazine in 3,4-Methylenedioxymethamphetamine-Positive Urine Samples

Historically, ecstasy tablets contained 3,4-methylenedioxymethamphetamine (MDMA) as the psychoactive component. In recent years, the Drug Enforcement Administration (DEA) and other law enforcement agencies have seized ecstasy tablets that are comprised of psychoactive drugs or drug mixtures other th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of analytical toxicology 2010-10, Vol.34 (8), p.464-469
Main Authors: Dickson, Amber J., Vorce, Shawn P., Holler, Justin M., Lyons, Timothy P.
Format: Article
Language:English
Subjects:
3,4-Methylenedioxyamphetamine - urine
Biological and medical sciences
Central Nervous System Stimulants - urine
Designer Drugs - analysis
Drug addictions
Humans
Medical sciences
N-Methyl-3,4-methylenedioxyamphetamine - urine
Piperazines - urine
Reproducibility of Results
Substance Abuse Detection - methods
Toxicology
Urinalysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Historically, ecstasy tablets contained 3,4-methylenedioxymethamphetamine (MDMA) as the psychoactive component. In recent years, the Drug Enforcement Administration (DEA) and other law enforcement agencies have seized ecstasy tablets that are comprised of psychoactive drugs or drug mixtures other than MDMA. Many jurisdictions have reported the presence of piperazine derivatives including 1-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)-piperazine (TFMPP), and 1-(3-chlorophenyl)-piperazine (mCPP) in ecstasy tablets. These piperazine derivatives produce stimulant and psychoactive effects similar to those produced by MDMA, amphetamine, and methamphetamine. In many countries, their use is not controlled, and therefore they have become a legal alternative to MDMA. For this study, a targeted population of 251 MDMA-positive urine samples were analyzed for designer drugs, including the piperazine derivatives. A basic liquid-liquid extraction followed by pentafluoropropionic anhydride (PFPA) derivatization and a full scan (m/z 42–550) gas chromatography-mass spectrometry analysis was used to screen the urine samples for 33 designer drugs. Overall, in 36% of the specimens analyzed, a stimulant or psychoactive compound other than MDMA and 3,4-methylenedioxyamphetamine (MDA) was detected. BZP, TFMPP, and mCPP were detected in 15%, 7%, and 1% of the samples, respectively.
ISSN:0146-4760
1945-2403
DOI:10.1093/jat/34.8.464